Fewer than one in 10 patients eligible to benefit from weight-loss injections such as Wegovy are able to get them, caution the World Health Organization as it issues its initial guidance on the drugs.
Considering in excess of 1,000,000,000 people worldwide now obese, it is urging broader and more equitable availability to this class of drugs.
Per forecasts, more than two billion could be obese by 2030 if no action is taken.
"The latest guidance affirms that obesity is a chronic disease that can be treated with comprehensive and continuous support," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are key hurdles to broad availability to the injections that can help people shift significant body mass, notes the organization.
Weight-Loss Drug Scarcity
Despite the current best projected outlook, the manufacturing of GLP-1 therapies might only reach approximately 100 million people – under 10% of the global need, as stated by the health organization.
The recommendation encourages nations and manufacturers to widen access, via approaches like patent sharing.
Exclusive production rights on the active ingredient – the primary component of the drug Wegovy – is scheduled to end in a number of nations in 2026.
How Weight-Loss Drugs Work
These medications replicate a body's own hormone to delay gastric emptying, suppress the appetite and boost satiety so individuals consume fewer calories.
Patients usually see weight reduction after several weeks of commencing the weekly injections.
Studies suggests users may put most of the weight back on within a year of stopping the drug, because their usual food cravings return.
Being above a healthy weight raises your chance for experiencing medical conditions, like type 2 diabetes, cardiovascular issues, stroke, and specific malignancies.
Excess weight impacts individuals in all nations and was associated with over three and a half million deaths worldwide in 2024, as per the WHO.
